vs
Side-by-side financial comparison of Blue Foundry Bancorp (BLFY) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Blue Foundry Bancorp is the larger business by last-quarter revenue ($13.3M vs $12.6M, roughly 1.1× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -27.4%, a 278.1% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 34.2%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 16.0%).
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
BLFY vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $12.6M |
| Net Profit | $-3.5M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -27.4% | 250.7% |
| Revenue YoY | 34.2% | 24080.8% |
| Net Profit YoY | -30.6% | 250.9% |
| EPS (diluted) | $-0.18 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $12.6M | ||
| Q3 25 | $12.6M | $0 | ||
| Q2 25 | $12.0M | $0 | ||
| Q1 25 | $11.1M | $12.0K | ||
| Q4 24 | $9.9M | $52.0K | ||
| Q3 24 | $9.5M | $65.0K | ||
| Q2 24 | $10.1M | $114.0K | ||
| Q1 24 | $9.9M | $140.0K |
| Q4 25 | $-3.5M | $31.5M | ||
| Q3 25 | $-1.9M | $-7.4M | ||
| Q2 25 | $-2.0M | $-1.7M | ||
| Q1 25 | $-2.7M | $-13.9M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-4.0M | $-17.1M | ||
| Q2 24 | $-2.3M | $-17.9M | ||
| Q1 24 | $-2.8M | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | -27.4% | 250.7% | ||
| Q3 25 | -14.8% | — | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | -24.2% | -115550.0% | ||
| Q4 24 | -28.4% | — | ||
| Q3 24 | -42.7% | -26380.0% | ||
| Q2 24 | -23.2% | -15668.4% | ||
| Q1 24 | -28.8% | -9049.3% |
| Q4 25 | $-0.18 | $0.56 | ||
| Q3 25 | $-0.10 | $-0.13 | ||
| Q2 25 | $-0.10 | $-0.03 | ||
| Q1 25 | $-0.13 | $-0.25 | ||
| Q4 24 | $-0.12 | — | ||
| Q3 24 | $-0.19 | $-0.32 | ||
| Q2 24 | $-0.11 | $-0.33 | ||
| Q1 24 | $-0.13 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.1M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $312.7M | $59.0M |
| Total Assets | $2.2B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.1M | $40.3M | ||
| Q3 25 | $44.1M | $48.6M | ||
| Q2 25 | $41.9M | $31.2M | ||
| Q1 25 | $46.2M | $48.9M | ||
| Q4 24 | $42.5M | $52.9M | ||
| Q3 24 | $76.1M | $76.3M | ||
| Q2 24 | $60.3M | $63.5M | ||
| Q1 24 | $53.8M | $82.3M |
| Q4 25 | $312.7M | $59.0M | ||
| Q3 25 | $314.4M | $26.5M | ||
| Q2 25 | $321.3M | $32.8M | ||
| Q1 25 | $326.7M | $33.8M | ||
| Q4 24 | $332.2M | $46.1M | ||
| Q3 24 | $339.3M | $65.5M | ||
| Q2 24 | $345.6M | $80.5M | ||
| Q1 24 | $350.2M | $96.2M |
| Q4 25 | $2.2B | $68.9M | ||
| Q3 25 | $2.2B | $54.2M | ||
| Q2 25 | $2.1B | $62.1M | ||
| Q1 25 | $2.1B | $77.7M | ||
| Q4 24 | $2.1B | $110.5M | ||
| Q3 24 | $2.1B | $135.2M | ||
| Q2 24 | $2.0B | $149.9M | ||
| Q1 24 | $2.0B | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.0M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.0M | $-8.4M | ||
| Q3 25 | $-255.0K | $17.4M | ||
| Q2 25 | $2.0M | $-17.7M | ||
| Q1 25 | $-3.8M | $-4.0M | ||
| Q4 24 | $5.1M | $-23.4M | ||
| Q3 24 | $-3.7M | $12.8M | ||
| Q2 24 | $14.1M | $-18.7M | ||
| Q1 24 | $-4.9M | $5.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-4.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -49.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
